Walleye Capital
PTGX icon

Walleye Capital’s Protagonist Therapeutics PTGX Stock Holding History

Walleye Capital’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.25M Buy
30,800
+7,200
+31% +$637K 0.01% 1081
2025
Q4 		$2.06M Buy
+23,600
New +$1.93M 0.01% 1852
2023
Q3 		– Sell
-2,100
Closed -$58K – 5239
2023
Q2 		$58K Sell
2,100
-3,200
-60% -$80.1K ﹤0.01% 3609
2023
Q1 		$122K Buy
+5,300
New +$89K ﹤0.01% 2818

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Walleye Capital's PTGX Position: Q4 2024 in Review

Walleye Capital sold out of Protagonist Therapeutics (PTGX) in Q4 2024, closing a stake of 105,335 shares — an estimated $4.74M sold.

Walleye Capital first reported a position in PTGX in Q3 2021 and held it in 12 quarters. The position peaked at $5.72M in Q4 2022. 241 funds tracked by Wall St. Rank hold PTGX as of Q4 2024.

  • Walleye Capital reported no remaining Protagonist Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Walleye Capital sold 105,335 Protagonist Therapeutics shares in Q4 2024, an estimated $4.74M.
  • Walleye Capital first reported a position in Protagonist Therapeutics in Q3 2021 and held it in 12 quarters.
  • Walleye Capital's Protagonist Therapeutics position peaked at $5.72M in Q4 2022.
  • 241 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2024.

Based on Walleye Capital's 13F filing for Q4 2024, filed 13 Feb 2025.